Niki BioSolutions, Inc. Common Stock

Day range

$1.90 – $2.05

Open

$2.00

Prev close

$1.83

Volume

10.93K

Market cap

$1.49M

Shares out

814.38K

• Cfo appointmentOct 13, 2026

  On October 9, 2026, the Board of Directors (the "Board") of Niki BioSolutions, Inc. ... appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing as of September 1, 2026, unless terminated sooner by either party.

• Underwriting agreementOct 9, 2026

  On October 9, 2026, Niki BioSolutions, Inc. entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets. The Sales Agreement provides for the sale and issuance of the Company's common stock from time to time through or to Wainwright as sales agent and/or principal.

• Investor presentationSep 14, 2026

  We are filing this report to disclose our corporate PowerPoint presentation. The presentation is furnished as an exhibit to this Current Report on Form 8-K.

• Equity compensation grantSep 4, 2026

  Mr. Mireskandari ... was granted 20,000 restricted stock units (RSUs) vesting immediately at the closing of the merger transaction and options to purchase 800,000 shares of the Company's common stock under the Company's 2026 Equity Incentive Plan, subject to the vesting conditions set forth in the Mireskandari Employment Agreement.

• Merger completionAug 21, 2026

  on that same day (the "Closing Date"), after obtaining the requisite shareholder approval and satisfying the closing conditions, Niki BioSolutions, Inc. (formerly known as Aptorum Group Limited, a Cayman Islands exempted company with limited liability ("Aptorum")) (the "Company") consummated its previously announced merger (the "Closing") pursuant to that certain Agreement and Plan of Merger on July 14, 2025, (the "Merger Agreement"), between Aptorum and DiamiR Biosciences Corp., a Delaware corporation ("DiamiR"), pursuant to which, among other matters, Aptorum was to form a direct, wholly owned subsidiary in the state of Delaware ("Merger Sub"). On July 20, 2026, immediately following the Domestication, Merger Sub merged with and into DiamiR in accordance with the applicable provisions of the DGCL, with DiamiR continuing as the surviving company and a wholly-owned subsidiary of Aptorum (the "Merger").

Days to cover

1.0

Short interest

14.6K

Avg volume

46.78K

As of Sep 30, 2026 · reported to FINRA twice monthly.